Evidence map›Paper›PMID 26101952›Full record

ArticleMolecular medicine (Cambridge, Mass.)2015

Administration of α-Galactosylceramide Improves Adenine-Induced Renal Injury.

Cristhiane Favero Aguiar, Cristiane Naffah-de-Souza, Angela Castoldi, Matheus Corrêa-Costa, Tárcio T Braga, Érika L Naka, Mariane T Amano, Débora T R S Abate, Meire I Hiyane, Marcos A Cenedeze and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Roles of Natural Killer T Cells and Natural Killer Cells in Kidney Injury.International journal of molecular sciences · 2019
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Cristhiane Favero AguiarLaboratory of Clinical and Experimental Immunology, Nephrology Division, Federal University of São Paulo, São Paulo, Brazil.
Cristiane Naffah-de-SouzaLaboratory of Transplantation Immunobiology, Department of Immunology, Institute of Biomedical Sciences IV, University of São Paulo, São Paulo, Brazil.
Angela CastoldiLaboratory of Transplantation Immunobiology, Department of Immunology, Institute of Biomedical Sciences IV, University of São Paulo, São Paulo, Brazil.
Matheus Corrêa-CostaLaboratory of Transplantation Immunobiology, Department of Immunology, Institute of Biomedical Sciences IV, University of São Paulo, São Paulo, Brazil.
Tárcio T BragaLaboratory of Transplantation Immunobiology, Department of Immunology, Institute of Biomedical Sciences IV, University of São Paulo, São Paulo, Brazil.
Érika L NakaLaboratory of Clinical and Experimental Immunology, Nephrology Division, Federal University of São Paulo, São Paulo, Brazil.
Mariane T AmanoLaboratory of Transplantation Immunobiology, Department of Immunology, Institute of Biomedical Sciences IV, University of São Paulo, São Paulo, Brazil.
Débora T R S AbateLaboratory of Transplantation Immunobiology, Department of Immunology, Institute of Biomedical Sciences IV, University of São Paulo, São Paulo, Brazil.
Meire I HiyaneLaboratory of Transplantation Immunobiology, Department of Immunology, Institute of Biomedical Sciences IV, University of São Paulo, São Paulo, Brazil.
Marcos A CenedezeLaboratory of Clinical and Experimental Immunology, Nephrology Division, Federal University of São Paulo, São Paulo, Brazil.
Alvaro Pacheco e Silva FilhoLaboratory of Clinical and Experimental Immunology, Nephrology Division, Federal University of São Paulo, São Paulo, Brazil.
Niels O S CâmaraLaboratory of Clinical and Experimental Immunology, Nephrology Division, Federal University of São Paulo, São Paulo, Brazil.
Universidade de São Paulo · BRUniversidade Federal de São Paulo · BRHospital Israelita Albert Einstein · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer T (NKT) cells are a subset of lymphocytes that reacts to glycolipids presented by CD1d. Invariant NKT cells (iNKT) correspond to >90% of the total population of NKTs and reacts to α-galactosylceramide (αGalCer). αGalCer promotes a complex mixture of Th1 and Th2 cytokines, as interferon (IFN)-γ and interleukin (IL)-4. NKT cells and IFN-γ are known to participate in some models of renal diseases, but further studies are still necessary to elucidate their mechanisms. The aim of our study was to analyze the participation of iNKT cells in an experimental model of tubule-interstitial nephritis. We used 8-wk-old C57BL/6j, Jα18KO and IFN-γKO mice. They were fed a 0.25% adenine diet for 10 d. Both adenine-fed wild-type (WT) and Jα18KO mice exhibited renal dysfunction, but adenine-fed Jα18KO mice presented higher expression of kidney injury molecule-1 (KIM-1), tumor necrosis factor (TNF)-α and type I collagen. To analyze the role of activated iNKT cells in our model, we administered αGalCer in WT mice during adenine ingestion. After αGalCer injection, we observed a significant reduction in serum creatinine, proinflammatory cytokines and renal fibrosis. However, this improvement in renal function was not observed in IFN-γKO mice after αGalCer treatment and adenine feeding, illustrating that this cytokine plays a role in our model. Our findings may suggest that IFN-γ production is one of the factors contributing to improved renal function after αGalCer administration.

Indexed as

AdenineAnimalsAntigens, CD1dCollagen Type IGalactosylceramidesHepatitis A Virus Cellular Receptor 1HumansInterferon-gammaInterleukin-4Kidney TubulesMembrane ProteinsMiceMice, KnockoutNatural Killer T-CellsNephritisRenal InsufficiencyAdeninealpha-galactosylceramideAntigens, CD1dCD1D protein, humanCollagen Type IGalactosylceramidesHavcr1 protein, mouseHepatitis A Virus Cellular Receptor 1IL4 protein, humanInterferon-gammaInterleukin-4Membrane ProteinsTumor Necrosis Factor-alpha

Identifiers

PMID26101952
PMCPMC4607613
OpenAlexW2419225884

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.